NEW YORK (GenomeWeb News) – Swiss proteomics firm Biognosys said this week that it has secured $1.0 million in funding in the form of a convertible loan.
The company, which specializes in targeted proteomics and mass spec-based biomarker discovery, said it will use the money to expand its commercial operations and product development.
Biognosys was spun out of Ruedi Aebersold's laboratory in 2008 at the Swiss Federal Institute of Technology.
Biognosys also announced a pair of personnel moves, appointing Russell Golson as director of sales and Lukas Reiter as head of research and development.